NHS CCG Commissioner Information

The Dermatology Solution

Referrals of patients with skin lesions to secondary care under the urgent 2ww rule are increasing, incurring rising costs for CCGs and placing significant strain on hospital waiting times.

70% of those referrals could be avoided if GPs had access to a rapid diagnostic service for skin lesions.

TELEDerm® is an award-winning tele-dermatolgy service which provides GPs with a ‘next day’ diagnosis by a MOLE Clinic® specialist expert in dermoscopy.

The service helps GPs reduce avoidable referrals to secondary care.

It is recommended for use by GPs and practice nurses prior to referring any patient with a suspect skin lesion to secondary care under the urgent 2 week wait rule.

The Dermatology Solution (Copy)

The Value For Money Solution

A GP or nurse uses a smartphone to access the secure, web-based TELEDerm® App to record relevant patient and lesion history. The App is free for NHS users.

The user then attaches a dermatoscope to the smartphone to add clinical and dermoscopic images of the lesion to the form. There are a number of high quality, low-cost dermatoscopes to choose from, including Handyscope by Fotofinder.

The form is then electronically and securely transferred via WIFI to MOLE Clinic® specialists for review.

A TELEDerm® consultation with a patient normally takes around 5 minutes.

Reports are issued in .pdf format for the GP or nurse to attach to the surgery’s electronic patient record or for onward transmission to secondary care if required.

CCGs are charged a low cost report fee on a ‘pay per use’ basis.

TELEDerm App (Copy)

The Compliant Solution

The service is compliant with NICE Guideline [NG14], which recommends that all pigmented skin lesions that are referred for assessment should be assessed ‘using dermoscopy carried out by healthcare professionals trained in this technique.’

The service is also compliant with NHS Digital guidelines to provide assurance that we practise good data security and that personal information is handled correctly.

Reports are issued in .pdf format for the GP or nurse to attach to the surgery’s electronic patient record or for onward transmission to secondary care if required.

Because our service supplies GPs with Diagnostic Reports in .pdf format (to attach to a patient’s record) and not with ‘IT systems or technology’, we are exempt from NHS Digital’s requirement for integration with existing NHS IT systems.

Most TELEDerm® reports are issued to GPs on a next day basis, with a diagnosis and recommendation in line with UK clinical guidelines.

nice-nhsd2.jpg

TELEDerm Outcomes

From 1/1/19 to 31/12/19, our clinicians supplied 9,007 TELEDerm® reports to NHS GPs and achieved an average response time of just 0.2 days. Of the 9,007 reports supplied, 6,696 or 74.3% confirmed that a referral to secondary care was not required.

That means nearly 7,000 patients received fast, welcome reassurance that their mole or sore was not skin cancer and a hospital appointment was not required.

It also means that 7,000 fewer patients attended hospital, significantly reducing pressure on hospital waiting times and helping ensure patients referred under the 2ww scheme are seen within targeted timescales.

 The MOLE Clinic has been providing this service to the NHS since 2008 and is proud of it’s 100% claims-free record.

TELEDerm Outcomes (Copy)
TELEDerm® has become an extremely effective, quick, cost efficient & safe skin lesion referral service for Doncaster patients. The feedback from patients and GPs has been extremely positive. TELEDerm® provides an invaluable & innovative primary care tool for Doncaster practices in dealing with an escalating dermatology caseload.
— Karl Roberts, Commissioner, NHS Doncaster CCG

(1) M.A. Syed et al, University of Herts 2012. Study assessed dermatology referrals to hospital from an 8 GP practice with a population of 12,800. Whilst referrals for skin conditions were most appropriate (almost 100%), referrals for skin lesions were least appropriate (each GP referred an average of 18.5 patients with skin lesions per year and 75% of those referred as suspect cancers were benign).